ROC analysis was used to calculate the area under the curve (AUC) of CD8 T cell, CD4 T cell, CD16 + 56+, D-Dimer, and MFS in 143 NSCLC patients with stage III lung cancer (ATB, n = 47; non-ATB, n = 96). This evidence concerns the gene CD8A and non-small cell lung carcinoma.